Australia Archives

News and Trends 8 Nov 2022

Telix Pharmaceuticals sees positive results in kidney cancer imaging study

Telix Pharmaceuticals Limited said it has highly positive top-line results from its pivotal phase III study of its investigational renal (kidney) cancer positron emission tomography (PET) imaging agent, TLX250-CDx (89 Zr- DFO-girentuximab). The ZIRCON study (Zirconium in Renal Cancer Oncology, NCT03849118) has met its co-primary and secondary endpoints. The study results delivered 86% sensitivity and […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

Best in Biotech 18 Oct 2022

The hottest private biotech companies in Australia

Australia has a strong base in biotechnology, with many incentives for R&D and commercialization. Here are the top five private Australian biotech companies that have recently showcased the country’s credentials in the sector. Australia is a highly developed nation in the Southern Hemisphere. Famous for its huge wool trade and iron ore wealth, the country […]

October 18, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 14 Oct 2022

A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation

A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions is to collaborate with Bristol Myers Squibb to discover molecular glue targets for protein degradation. A-Alpha will identify and characterize novel pairs of E3 ubiquitin ligases and targets that Bristol Myers Squibb will utilize for potential design and development of […]

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Adalta and GPCR Therapeutics to collaborate on novel cancer treatments

AdAlta Limited and GPCR Therapeutics Inc, are set to collaborate to evaluate AdAlta’s CXCR4 inhibiting i‑bodies as cancer therapeutics, using GPCR Therapeutics’ combination inhibition approach. AdAlta said its i-body platform is suited to engaging an important class of drug targets called G-protein coupled receptors (GPCRs). One of these GPCRs is known as CXCR4. In addition […]

October 13, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 26 Sep 2022

Australian Agilex Biolabs expands its capacity with new toxicology testing facility

A toxicology facility with more than 10,000 sq ft of laboratory space has opened in Australia and will help Agilex Biolabs expand its capacity to serve the biotech, pharma and animal health industries. After more than 25 years in the industry, Agilex Biolabs says it will now be able to share with an even more […]

September 26, 2022 - 2 minutesmins - By Liza Laws

News and Trends 22 Sep 2022

Study data for glioblastoma treatment confirms safety and tolerability profile

The final results of a phase 1/2 study of a therapy in recurrent glioblastoma multiforme (GBM) have been reported by Australian-based Telix Pharmaceuticals Ltd. The therapy, TLX101 (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) administered with external beam radiation therapy (EBRT) and the primary objective was to evaluate and test the safety and tolerability profile of the intravenous therapy […]

September 22, 2022 - 4 minutesmins - By Liza Laws

News and Trends 22 Sep 2022

Emyria starts program with neuroscience drug discovery CRO

Emyria Limited, a clinical stage biotech, is set to work with PsychoGenics, a specialist neuroscience preclinical drug discovery and contract research organization (CRO). Emyria and partner, the University of Western Australia, will start by screening five novel MDMA analogs from their proprietary library using PsychoGenic’s drug discovery platform, SmartCube. SmartCube extracts and analyzes behavioral and […]

September 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Pancreatic cancer study using dual-cell therapy yields positive results

Australian biotech company Noxopharm Limited has revealed encouraging new preclinical data from its long-term collaboration with UNSW Sydney. The results were reported this week at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer in Boston. The study involves Noxopharm’s novel preclinical drug, which attacks pancreatic cancer in a different and innovative […]

September 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 13 Sep 2022

Starpharma announces new data for prostate cancer trial

Cabazitaxel (Jevtana, Sanofi) is a chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP cabazitaxel is a patented, highly water soluble dendrimer nanoparticle version of standard cabazitaxel that has shown, in preclinical and clinical studies, benefits in terms of safety and efficacy. In a poster presentation at ESMO […]

September 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 1 Sep 2022

License agreement signed allowing drug to treat mycosis fungoides to expand in Asia, Australia and the Middle East

A license agreement has been signed between Helsinn Group and Juniper Biologics further widening the scope for distribution of T-cell lymphoma treatment, LEGADA. The license signifies a supply agreement to register, distribute, promote, market and sell the drug in Australia, Asia and the Middle East as a topical treatment of the mycosis fungoides-type cutaneous T-cell […]

September 1, 2022 - 3 minutesmins - By Liza Laws

Best in Biotech 19 Aug 2022

Five emerging biotech hubs in the Asia-Pacific region

The Asia-Pacific (APAC) region is the third largest pharmaceutical market in the world, and has seen a shift from predominantly producing generics to developing innovative technologies. Here are five emerging biotech hubs in the region to keep an eye on. The life sciences industry is seeing rapid growth in the APAC region – home to […]

August 19, 2022 - 7 minutesmins - By Omnia Ibrahim

News and Trends 18 Aug 2022

Carina Biotech raises funds for colorectal cancer research

Australia’s Carina Biotech has raised A$7.5 million (US$5.2 million) at first close of its current funding round. Venture capital business Tenmile was the cornerstone investor, with support from existing investors. The capital raise enables Carina Biotech to complete its Investigational New Drug (IND) enabling studies and initiate a CAR-T clinical trial of its LGR5 CAR-T […]

August 18, 2022 - 2 minutesmins - By Jim Cornall

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us